OncoMatch/Clinical Trials/NCT06458439
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
Is NCT06458439 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Epcoritamab for lymphoma, non-hodgkin.
Treatment: Epcoritamab — This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20+ tumor cells)
Documented CD20+ tumor cells on most recent biopsy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anthracycline — frontline
Must have received: anti-cd20 antibody — frontline
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Abramson Cancer Center at the University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06458439 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received anthracycline and anti-cd20 antibody.
Does this trial require MS4A1?
Yes, MS4A1 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify